Trials / Completed
CompletedNCT02157077
Aflibercept After Ranibizumab in Exudative Age-related Macular Degeneration
A Phase III b, Multicenter Study of the Efficacy and Safety of Aflibercept Switch in Patients With Exudative AMD With Detachment of the Retinal Pigment Epithelium and Previously Treated With Ranibizumab Intravitreal Injection. (ARI2)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 90 (actual)
- Sponsor
- Centre Hospitalier Intercommunal Creteil · Academic / Other
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the current study is to evaluate the ability of Eylea to induce a regression of PED height on patients previously extensively treated by Lucentis. The regimen proposed for this study is the 3 monthly injection followed by a 6 weeks interval injection until week 26.
Detailed description
The regimen proposed for this study is the 3 monthly injection followed by a 6 weeks interval injection until week 26.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Aflibercept | Intravitreal Injection |
Timeline
- Start date
- 2013-12-01
- Primary completion
- 2015-12-01
- Completion
- 2015-12-01
- First posted
- 2014-06-05
- Last updated
- 2022-12-06
Locations
9 sites across 1 country: France
Source: ClinicalTrials.gov record NCT02157077. Inclusion in this directory is not an endorsement.